Addex First Half 2007 Financial Results Next Wednesday

Addex Prices IPO Shares at CHF73, raises CHF137 million

Addex appoints Head of IR and Communications

Addex Launches IPO on SWX Swiss Exchange

Addex Pharmaceuticals Plans IPO on SWX Swiss Exchange

Addex reports positive results in Phase IIa clinical trial with ADX10059 in Migraine

Addex achieves statistically significant outcome in Phase IIa clinical trial with ADX10059 in Gastro-Esophageal Reflux Disease

Addex initiates Phase I trials on ADX48621, a novel compound for treatment of Depression, Anxiety Disorder and Pain

Addex starts Phase IIa Proof of Concept Study on ADX10061 for Smoking Cessation

Addex begins Phase IIa Proof of Concept Study on ADX10059 for Treatment of Acute Anxiety